CEP55

Across TCGA pan-cancer cohorts, CEP55 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP55 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEP55 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP55 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, OV, and LSCC are the cancer types where CEP55 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.149	0.591	.001	22	view →
OV	DFS	Tertile	All	0.420	1.000	.019	12	view →
LSCC	DFS	Quartile	All	1.000	0.206	.006	11	view →
CCRCC	DFS	Median	II,III,IV	0.297	0.808	.016	7	view →
GBM	OS	Median	All	0.436	0.607	.022	4	view →
HNSC	OS	Tertile	IV	0.840	0.607	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP55–PDAC (DFS)

Open the PDAC breakdown →